575 abstracts found.



Results filter

PET-PANC: Multi-centre trial of 18Fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.

Year:

Session type:

Paula Ghaneh1,Wai-Lup Wong2,Sobhan Vinjamuri3,Colin Johnson4,Mohamed Abu Hilal5,Antony Higginson6,Andrew Smith7,Andrew Scarsbrook8,Colin Mckay9,Robert Sutcliffe10,Hemant Kocher11,David Cunningham12,Stephen Pereira13,Brian Davidson14,David Chang15,Saboor Khan16,Bal Sanghera17,Andrew Titman18,Gillian Lancaster19,Catrin Plumpton20,Seow Tien Yeo21,Robert Hanson22,Christopher Halloran23,John Neoptolemos23
1University of Liverpool,2Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK,3Royal Liverpool and Broadgreen University Hospitals NHS Trust,4Faculty of Medicine, University of Southampton, Southampton, UK.,5Department of Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK.,6Department of Radiology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.,7Department of Gastrointestinal Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK.,8Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.,9Department of Surgery, Glasgow Royal Infirmary - NHS Greater Glasgow and Clyde, Glasgow, UK.,10Department of Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.,11Barts Cancer Institute, Barts and the London, London, UK.,12Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London, UK.,13Institute for Liver and Digestive Health, University College London Hospitals NHS Foundation Trust, London, UK.,14Department of Surgery, Royal Free London NHS Foundation Trust, London, UK.,15Department of Surgery, Royal Blackburn Hospital- East Lancashire Hospitals NHS Trust, Blackburn,UK.,16Department of Surgery, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.,17Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK.,18Department of Mathematics and Statsistics, Lancaster University, Lancaster, UK,19Department of Mathematics and Statsistics, Lancaster University, Lancaster, UK.,20Centre for Health Economics and Medicines Evaluation, Bangor University, Lancaster, UK.,21Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, UK.,22Liverpool Cancer Research UK Cancer Trials Unit, University of Liverpool, Liverpool, UK,23Department Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.

Understanding different types of cervical screening non-participant: a population-based survey

Year:

Session type:

Jo Waller1,Jessica Haddrell2,Amanda Chorley2,Rebecca Ferrer3,Laura Marlow2
1University College London,2UCL,3NCI

Updated results from a phase 3 trial of nivolumab combined with ipilimumab in treatment-naive patients with advanced melanoma (CheckMate 067)

Year:

Session type:

Jedd Wolchok1,Vanna Chiarion-Sileni2,Rene Gonzalez3,Piotr Rutkowski4,Jean-Jacques Grob5,C. Lance Cowey6,Christopher Lao7,Dirk Schadendorf8,Pier Ferrucci9,Michael Smylie10,Reinhard Dummer11,Andrew Hill12,John Haanen13,Michele Maio14,Grant McArthur15,Dana Walker16,Joel Jiang16,Christine Horak16,James Larkin17,F. Stephen Hodi18
1Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College,2Oncology Institute of Veneto IRCCS,3University of Colorado Cancer Center,4Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology,5Hospital de la Timone,6Texas Oncology-Baylor Charles A. Sammons Cancer Center,7University of Michigan,8Department of Dermatology, University of Essen,9European Institute of Oncology,10Cross Cancer Institute,11Universitäts Spital,12Tasman Oncology Research,13Netherlands Cancer Institute,14University Hospital of Siena,15Peter MacCallum Cancer Centre,16Bristol-Myers Squibb,17Royal Marsden Hospital,18Dana-Farber Cancer Institute

The molecular epidemiology of rare and compound EGFR mutations in 14,304 non-small cell lung carcinomas

Year:

Session type:

Matthew Evans1,Brendan O'Sullivan1,Frances Hughes1,Claire Swift1,Reena Dessi1,Tina Mullis1,Matthew Smith1,Philippe Taniere1
1Queen Elizabeth Hospital Birmingham

Immune-derived PD-L1 gene expression defines a subgroup of stage II/III colorectal cancer patients with favorable prognosis that may be harmed by adjuvant chemotherapy

Year:

Session type:

Philip Dunne1,Darragh McArt2,Paul O'Reilly2,Helen Coleman2,Maurice Loughrey2,Wendy Allen2,Simon McDade2,Sandra van Scaheybroeck2,Manuel Salto-Tellez2,Daniel Longley2,Mark Lawler2,Patrick Johnston2
1CCRCB Queen's University Belfast,2QUB

Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing

Year:

Session type:

Jonas Demeulemeester1,Parveen Kumar2,Elen K. Møller3,Silje Nord3,David C. Wedge4,April Peterson5,Randi R. Mathiesen6,Renathe Fjelldal7,Masoud Zamani Esteki8,A. Jason Grundstad9,Elin Borgen7,Lars O. Baumbusch10,Anne-Lise Børresen-Dale3,Kevin P. White9,Bjørn Naume11,Vessela N. Kristensen3,Peter Van Loo1,Thierry Voet2
1The Francis Crick Institute, London, UK / Human Genome Laboratory, Department of Human Genetics, University of Leuven, Leuven, Belgium,2Laboratory of Reproductive Genomics, Department of Human Genetics, University of Leuven, Leuven, Belgium / Single-cell Genomics Centre, Wellcome Trust Sanger Institute, Hinxton, UK,3Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway / K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway,4Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK,5Institute for Genomics & Systems Biology and Department of Human Genetics, University of Chicago, Chicago, Illinois, USA / (Present address) Laboratory of Genetics, University of Wisconsin, Madison, Wisconsin, USA,6Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway / Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway / (Present address) Department of Oncology, Akershus University Hospital, Lørenskog, Norway,7Department of Pathology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway,8Laboratory of Reproductive Genomics, Department of Human Genetics, University of Leuven, Leuven, Belgium,9Institute for Genomics & Systems Biology and Department of Human Genetics, University of Chicago, Chicago, Illinois, USA,10Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway / (Present address) Department of Pediatric Research, Women and Children's Division, Oslo University Hospital, Rikshospitalet, Oslo, Norway,11K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway / Division of Surgery and Cancer Medicine, Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway

Ten year trends of participation of teenagers and young adults (TYA) in selected NIHR National Cancer Research Network trials

Year:

Session type:

Lorna Fern1,Seema Alexander1,Jeremy Whelan2
1National Cancer Research Institute,2University College London Hospitals NHS Foundation Trust

A Hypoxia Transcriptomic Signature Predicting Benefit from Hypoxia-modifying Treatment for High Risk Bladder Cancer Patients

Year:

Session type:

Lingjian Yang1,Amanda Williamson1,Joely Irlam1,Helen Denley2,Peter Hoskin3,Ananya Choudhury1,Catharine West1
1University of Manchester,2Manchester Royal Infirmary,3Mount Vernon Hospital

Why don’t drug companies provide access to drug for use in combination with RT?

Year:

Session type:

Anthony Chalmers1
1Glasgow Centre for Cancer Research

Patients and families urge palliative care to prioritise the financial cost of caregiving; reporting from the Palliative and End of life care Priority Setting Partnership (PeolcPSP); a national survey

Year:

Session type:

Despina Anagnostou1,Jordan VanGodwin1,Anthony Byrne1,Annmarie Nelson1
1Cardiff University

Non surgical treatment of operable rectal cancer: Reducing harm from the standard of care in elderly patients

Year:

Session type:

Arthur Sun Myint1,Fraser Smith2,Karen Whitmarsh1,Helen Wong1,Mark Pritchard3
1Clatterbridge Cancer Centre,2Royal Liverpool and Broadgreen University Hospital,3Department of Cellular and Molecular Physiology,University of Liverpool

Dosimetric analysis of VMAT for locally advanced pancreatic cancer and a novel duodenal-PTV overlap parameter as a predictor of feasibility of dose escalation

Year:

Session type:

Paul Junni1,Ganesh Radhakrishna1
1NHS

A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic nodal irradiation

Year:

Session type:

Ciara Lyons1,Raymond King2,Sarah Osman2,Joe O'Sullivan3,Alan Hounsell3,Suneil Jain2,Conor McGarry3
1Centre for Cancer Research and Cell Biology,2Centre for Cancer Research and Cell Biology, Queen's University Belfast,3Northern Ireland Cancer Centre, Belfast Health and Social Care Trust

A higher whole pelvic integral dose is associated with worsening fatigue and functional outcome in prostate cancer patients treated with intensity modulated radiotherapy

Year:

Session type:

Nuradh Joseph1,Tiziana Rancati2,Alessandro Cicchetti2,Riccardo Valdagni2,Jenny Chang-Claude3,Susan Davidson4,Kerstie Johnson5,Chris Talbot6,Adam Webb6,Alan McWilliam4,Catharine West7,Ananya Choudhury4
1Ministry of Health, Sri Lanka,2Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.,3German Cancer Research Center (DKFZ), Heidelberg, Germany.,4The Christie NHS Foundation Trust,5Universtiy of Leicester, United Kingdom,6University of Leicester, United Kingdom,7Institute of Cancer Sciences, University of Manchester, UK.

The war on prevention: Bellicose cancer metaphors undermine prevention behaviors

Year:

Session type:

David Hauser1
1University of Michigan

Keeping the Customer Satisfied? #5 – Who’s Talking? Findings On Research Conversations From The National (English) Cancer Patient Experience Survey 2015

Year:

Session type:

Richard Stephens1,Matthew Baker2,Carolyn Morris2
1NCRI,2NCRI Consumer Forum

‘Searching for the new normal’: Exploring the role of language and metaphor in becoming a cancer survivor

Year:

Session type:

Lynda Appleton1
1Clatterbridge Cancer Centre

Enhancing responses to melanoma therapy with novel combinations of targeted therapy and immune checkpoint blockade

Year:

Session type:

Robert Szczepaniak Sloane1,Alexandre Reuben2,Ningping Feng2,Sarah Johnson2,Jill Garvey2,Jiong Chen2,Courtney Hudgens2,Luigi Nezi2,Teresa Manzo2,Mariana Pettaccia De Macedo2,John Miller2,Jianhua Hu2,Richard Davis2,Hong Jiang2,Peter Prieto2,Timothy Heffernan2,Elizabeth Burton2,Patrick Hwu2,Hussein Tawbi2,Alexander Lazar2,Michael T. Tetzlaff2,Joe Marszalek2,Willem Overwijk2,Zachary Cooper2,Michael A. Davies2,Jennifer A. Wargo2
1UT MD Anderson Cancer Center,2MD Anderson

Enhancing patient-centred care: Assessment and management of patients’ unmet needs

Year:

Session type:

Afaf Girgis1
1University of New South Wales

Immunotherapy and radiotherapy

Year:

Session type:

Tim Illidge1
1Cancer Research UK Manchester Institute

Novel drug/radiotherapy combinations

Year:

Session type:

Philippe Lambin1
1MAASTRO clinic/Maastricht University

The war on cancer: Reflections from a conscientious objector

Year:

Session type:

Andrew Graystone1
1Media Futures

REPORT-UK (Real-time Electronic Patient Outcome ReporTing of adverse events in UK cancer trials) – a feasibility pilot study in a UK oncology setting

Year:

Session type:

Fiona Kennedy1,Beverly Clayton1,Kate Absolom1,Elaine O’Connell Francischetto2,Louise Flintoff3,Kathryn Gordon1,Will Crocombe1,Victoria Hiley1,Julia Brown1,Jane M Blazeby4,Galina Velikova5
1University of Leeds,2University of Birmingham,3University Hospitals Bristol NHS Foundation Trust,4University of Bristol / University Hospitals Bristol NHS Foundation Trust,5University of Leeds / Leeds Teaching Hospitals NHS Trust

Human tumor virus infection and immune control in vivo

Year:

Session type:

Christian Münz1
1University of Zurich

Future prospects for novel therapeutics for EBV-associated diseases

Year:

Session type:

Lawrence Young1
1University of Warwick

Advances in the radiotherapy treatment of SCLC

Year:

Session type:

Corinne Faivre-Finn1
1University of Manchester

Pre-clinical mouse models of SCLC to identify and test novel therapies

Year:

Session type:

Julien Sage1
1Stanford University

Fear of cancer recurrence: Current state and future directions for research and clinical practice

Year:

Session type:

Gozde Ozakinci1
1University of St Andrews

Screening for distress in cancer: Does it influence uptake of care?

Year:

Session type:

Alex Mitchell1
1University of Leicester

Building a weight of evidence to prevent cancer in later life

Year:

Session type:

Gillian Rosenberg1,Lucie Hooper1,Jyotsna Vorhra1
1Policy Research Centre for Cancer Prevention, Cancer Research UK

Association between metabolic syndrome components and the risk of primary liver cancer and cirrhosis

Year:

Session type:

Paul Nderitu1,Hans Garmo2,Lars Holmberg2,Hakan Malmstrom3,Niklas Hammar3,Goran Walldius3,Ingmar Jungner3,Mats Lambe4,Mieke Van Hemelrijck2
1Guy's and St Thomas' NHS Trust Foundation,2King's College London,3Karolinska Institute,4Karolinske Institute

Improving effiency of phase II oncology trials using RECIST endpoints

Year:

Session type:

James Wason1
1MRC Biostatistics Unit

Personalised oncology in 2016: New paradigms in clinical trial methodology

Year:

Session type:

Richard Simon1
1National Cancer Institute

Tumour-size as a surrogate for overall survival in advanced colorectal cancer

Year:

Session type:

Tomasz Burzykowski1
1Hasselt University

National Lung Matrix Trial: successful implementation of a phase II umbrella trial testing multiple genetic-marker-directed drugs in advanced non-small cell lung cancer

Year:

Session type:

Lucinda Billingham1,Dee Wherton1,Laura Llewellyn1,Susannah Brown1,Sarah Johnson1,Peter Fletcher1,Clive Mulatero2,Timothy Yap3,Yvonne Summers4,James Spicer5,Rowena Sharpe6,Sanjay Popat7,Gary Middleton8
1Cancer Research UK Clinical Trials Unit, University of Birmingham,2Leeds Teaching Hospitals NHS Trust, Leeds,3Royal Marsden Hospital and Institute of Cancer Research, London,4The Christie NHS Foundation Trust, Manchester,5King's College London, and Guy's and St Thomas’ NHS Foundation Trust, London,6Cancer Research UK, London,7Royal Marsden Hospital and Imperial College, London,8Institute of Immunology and Immunotherapy, University of Birmingham

Genetic factors in NAFLD: Disease progression and hepatocellular carcinoma

Year:

Session type:

Quentin Anstee1
1Newcastle University

The TARGET trial: molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials

Year:

Session type:

Dominic Rothwell1,Mahmood Ayub1,Sakshi Gulati1,John Brognard1,Andrew Wallace2,Crispin Miller1,Emma J. Dean3,Natalie Cook3,Fiona Thistlethwaite3,Hui Sun Leong1,Helen Eaton2,Emma Howard2,Andrew Hudson3,Carla Siswick3,Joanne Dransfield3,Marianna Christodolou3,Nigel Smith1,Louise Carter3,Robert Metcalf3,Sreeja Aruketty3,Jaseela Chiramel3,Andrew Hughes3,Richard Marais1,Caroline Dive1,Ged Brady1,Matthew G. Krebs3
1CRUK Manchester Institute,2Central Manchester NHS Foundation Trust (CMFT),3Christie NHS Foundation Trust, Manchester

Mutational signatures reveal subgroups of distinct aetiology and new therapeutic opportunities in oesophageal adenocarcinoma

Year:

Session type:

Maria Secrier1
1Cancer Research UK Cambridge Institute, University of Cambridge

The changing face of cancer aftercare, what this means to patients and clinicians

Year:

Session type:

Jessica Corner1
1University of Nottingham

Development and testing of evidence-based psycho-educational interventions that can be readily adopted into clinical practice

Year:

Session type:

Penny Schofield1
1Swinburne University of Technology

Facilitating self-management and personalised access to supportive care

Year:

Session type:

Irma Verdonck de Leeuw1
1VU University Medical Center

Impact of Dementia on treatment of older patients with breast cancer. An interim analysis of the Bridging the Age Gap in Breast Cancer Study

Year:

Session type:

Osama Zaman1,Sue Ward2,Karen Collins3,Kwok-Leung Cheung4,Thompson Robinson5,Riccardo Audisio6,Oscar Bortolami7,Charlene Martin7,Malcolm Reed8,Lynda Wyld7
1University of Sheffield Medical School,2ScHARR, University of Sheffield,3Sheffield Hallam University,4The University of Nottingham,5University of Leicester,6University of Liverpool,7The University of Sheffield,8Brighton and Sussex Medical School

How to lower rate of upgrade of screen-detected high risk B3 breast lesions at time of surgery: A new proposed pathway

Year:

Session type:

Amrita Kumar1,Chin Ng1,Mohsen Elgammal2
1Frimley Health,2

Does Medial-To-Lateral Vs Lateral-To-Medial Approach Affect Short-Term Outcomes In Laparoscopic Colorectal Surgery?

Year:

Session type:

Anwar Hussain1,Andrew Torrance1,Saad Azhar1,Achillias Tsiamis1
1University Hospitals of North Midlands Stoke-on-Trent

The impact of co-morbidities on recovery from colorectal cancer within first 2 years after surgery: results from the UK Colorectal Wellbeing (CREW) cohort study

Year:

Session type:

Joanne Haviland1,Amanda Cummings1,Jane Winter1,Chloe Grimmett1,Lynn Calman1,Jessica Corner1,Amy Din1,Deborah Fenlon1,Christine M. May1,Alison Richardson1,Peter W. Smith1,Claire Foster1
1University of Southampton

Surgery for retroperitoneal sarcoma in the elderly

Year:

Session type:

Henry Smith1,Joseph Meirion Thomas1,Myles Smith1,Andrew Hayes1,Dirk Strauss1
1The Royal Marsden Hospital

Patterns of disease relapse in primary extremity soft tissue sarcoma

Year:

Session type:

Henry Smith1,Nikolaos Memos1,Joseph Meirion Thomas1,Myles Smith1,Dirk Strauss1,Andrew Hayes1
1The Royal Marsden Hospital

Oncological safety of lipofilling in patients with breast cancer: a meta-analysis and update to clinical practice

Year:

Session type:

Umar Wazir1,Hannah Headon1,Hiba El Hage Chehade1,Abdul , MD FRCS, 1 and 5. Kasem1,Kefah Mokbel1
1London Breast Institute

A first in human feasibility study of 18F-FDG Cerenkov luminescence imaging (CLI)for intraoperative assessment of tumour resection margins in breast-conserving surgery (BCS)

Year:

Session type:

Massimiliano Cariati1,Maarten Grootendorst1,Ashutosh Kothari2,Michael Douek1,Tibor Kovacs2,Hisham Hamed2,Amit Pawa2,Fiona Nimmo2,Vernie Ramalingam2,Sweta Sethi1,Sanjay Mistry1,Kunal Vyas3,David Tuch4,Alan Britten5,Mieke Van Hemelrijck1,Gary Cook1,Sarah Allen2,Christopher Sibley-Allen2,Sarah Pinder1,Arnie Purushotham1
1King's College London,2Guy's and St Thomas' NHS Foundation Trust,3Sagentia,4Lighpoint Medical Ltd,5St George's University Hospital NHS Foundation Trust

Variations in Ribonucleotide Reductase subunit expression induce gemcitabine resistance in a cell cycle dependent manner in Suit-2 pancreatic cancer cells

Year:

Session type:

Kulbir Mann1,Paula Ghaneh2,William Greenhalf2
1Royal Liverpool University Hospital,2University of Liverpool